Stearylated INF7 peptide enhances endosomal escape and gene expression of PEGylated nanoparticles both in vitro and in vivo

Journal of Pharmaceutical Sciences

Volumn 101, Issue 2, 2012, Pages 879-882

  El Sayed, Ayman ^a,b   Masuda, Tomoya ^a   Akita, Hidetaka ^a   Harashima, Hideyoshi ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

^b Alexandria University Faculty of Pharmacy   (Egypt)

Author keywords

Gene delivery; Gene vectors; Liposomes; Nanoparticles; Non viral gene delivery; PEGylation; Peptides; Plasmid DNA; Transfection

Indexed keywords

DIMYRISTOYLPHOSPHATIDYLETHANOLAMINE; DISTEAROYLPHOSPHATIDYLETHANOLAMINE; ETHANOLAMINE DERIVATIVE; INTERFERON; INTERFERON 7; LUCIFERASE; MACROGOL 2000; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; CHEMICAL MODIFICATION; CONCENTRATION (PARAMETERS); CONFOCAL LASER MICROSCOPY; ENDOSOME; GENE EXPRESSION; HELA CELL; HUMAN; HUMAN CELL; MALE; MOUSE; NANODEVICE; NANOENCAPSULATION; NONHUMAN; NOTE;

EID: 84455169465     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22807     Document Type: Article

References (26)

1. Audouy SA, de Leij LF, Hoekstra D, Molema G. 2002. In vivo characteristics of cationic liposomes as delivery vectors for gene therapy. Pharm Res 19(11):1599-1605.
2. Heyes J, Palmer L, Chan K, Giesbrecht C, Jeffs L, MacLachlan I. 2007. Lipid encapsulation enables the effective systemic delivery of polyplex plasmid DNA. Mol Ther 15(4):713-720.
3. Khalil IA, Kogure K, Futaki S, Harashima H. 2008. Octaarginine-modified liposomes: Enhanced cellular uptake and controlled intracellular trafficking. Int J Pharm 354(1-2):39-48.
4. Kamiya H, Akita H, Harashima H. 2003. Pharmacokinetic and pharmacodynamic considerations in gene therapy. Drug Discov Today 8(21):990-996.
5. Akita H, Harashima H. 2008. Advances in non-viral gene delivery: Using multifunctional envelope-type nano-device. Expert Opin Drug Deliv 5(8):847-859.
6. Kogure K, Akita H, Yamada Y, Harashima H. 2008. Multifunctional envelope-type nano device (MEND) as a non-viral gene delivery system. Adv Drug Deliv Rev 60(4-5):559-571.
7. Allen C, Dos Santos N, Gallagher R, Chiu GN, Shu Y, Li WM, Johnstone SA, Janoff AS, Mayer LD, Webb MS, Bally MB. 2002. Controlling the physical behavior and biological performance of liposome formulations through use of surface grafted poly(ethylene glycol). Biosci Rep 22(2):225-250.
8. Nicolazzi C, Mignet N, de la Figuera N, Cadet M, Ibad RT, Seguin J, Scherman D, Bessodes M. 2003. Anionic polyethyleneglycol lipids added to cationic lipoplexes increase their plasmatic circulation time. J Control Release 88(3):429-443.
9. Suh J, Choy KL, Lai SK, Suk JS, Tang BC, Prabhu S, Hanes J. 2007. PEGylation of nanoparticles improves their cytoplasmic transport. Int J Nanomedicine 2(4):735-741.
10. Mishra S, Webster P, Davis ME. 2004. PEGylation significantly affects cellular uptake and intracellular trafficking of non-viral gene delivery particles. Eur J Cell Biol 83(3):97-111.
11. Hatakeyama H, Akita H, Harashima H. 2011. A multifunctional envelope type nano device (MEND) for gene delivery to tumours based on the EPR effect: A strategy for overcoming the PEG dilemma. Adv Drug Deliv Rev 63(3):152-160.
12. Holland JW, Hui C, Cullis PR, Madden TD. 1996. Poly(ethylene glycol)-lipid conjugates regulate the calcium-induced fusion of liposomes composed of phosphatidylethanolamine and phosphatidylserine. Biochemistry 35(8):2618-2624.
13. Hafez IM, Cullis PR. 2001. Roles of lipid polymorphism in intracellular delivery. Adv Drug Deliv Rev 47(2-3):139-148.
14. Remaut K, Lucas B, Braeckmans K, Demeester J, De Smedt SC. 2007. Pegylation of liposomes favours the endosomal degradation of the delivered phosphodiester oligonucleotides. J Control Release 117(2):256-266.
15. Vandenbroucke RE, De Smedt SC, Demeester J, Sanders NN. 2007. Cellular entry pathway and gene transfer capacity of TAT -modified lipoplexes Biochim Biophys Acta 1768(3):571-579.
16. Kibria G, Hatakeyama H, Ohga N, Hida K, Harashima H. 2011. Dual-ligand modification of PEGylated liposomes shows better cell selectivity and efficient gene delivery. J Control Release 153(2):141-148.
17. El-Sayed A, Futaki S, Harashima H. 2009. Delivery of macromolecules using arginine-rich cell-penetrating peptides: Ways to overcome endosomal entrapment. AAPS J 11(1):13-22.
18. El-Sayed A, Masuda T, Khalil I, Akita H, Harashima H. 2009. Enhanced gene expression by a novel stearylated INF7.
19. Masuda T, Akita H, Nishio T, Niikura K, Kogure K, Ijiro K, Harashima H. 2008. Development of lipid particles targeted via sugar-lipid conjugates as novel nuclear gene delivery system. Biomaterials 29(6):709-723.
20. Ishitsuka T, Akita H, Harashima H. 2011. Functional improvement of an IRQ-PEG-MEND for delivering genes to the lung. J Control Release 154(1):77-83.
21. Iwasa A, Akita H, Khalil I, Kogure K, Futaki S, Harashima H. 2006. Cellular uptake and subsequent intracellular trafficking of R8-liposomes introduced at low temperature. Biochim Biophys Acta 1758(6):713-720.
22. El-Sayed A, Khalil IA, Kogure K, Futaki S, Harashima H. 2008. Octaarginine- and octalysine-modified nanoparticles have different modes of endosomal escape. J Biol Chem 283(34):23450-23461.
23. Ambegia E, Ansell S, Cullis P, Heyes J, Palmer L, MacLachlan I. 2005. Stabilized plasmid-lipid particles containing PEG-diacylglycerols exhibit extended circulation lifetimes and tumor selective gene expression. Biochim Biophys Acta 1669(2):155-163.
24. Mudhakir D, Akita H, Khalil IA, Futaki S, Harashima H. 2005. Pharmacokinetic analysis of the tissue distribution of octaarginine modified liposomes in mice. Drug Metab Pharmacokinet 20(4):275-281.
25. Khalil IA, Hayashi Y, Mizuno R, Harashima H. 2011. Octaarginine- and pH sensitive fusogenic peptide-modified nanoparticles for liver gene delivery. J Control Release.
26. Hayashi Y, Yamauchi J, Khalil IA, Kajimoto K, Akita H, Harashima H. 2011. Cell penetrating peptide-mediated systemic siRNA delivery to the liver. Int J Pharm 419(1-2):308-313.